Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
ABPRO CORP (ABP)ABP
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
11/20/2024: ABP (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: PASS |
Historic Profit: -16.01% | Upturn Advisory Performance  2 | Avg. Invested days: 44 |
| Profits based on simulation | Stock Returns Performance  1 | Last Close 11/20/2024 |
Type: Stock | Today’s Advisory: PASS |
Historic Profit: -16.01% | Avg. Invested days: 44 |
Upturn Star Rating | Stock Returns Performance 1 |
| Profits based on simulation Last Close 11/20/2024 | Upturn Advisory Performance 2 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 42.98M USD |
Price to earnings Ratio - | 1Y Target Price - |
Dividends yield (FY) - | Basic EPS (TTM) - |
Volume (30-day avg) 27291 | Beta - |
52 Weeks Range 3.18 - 13.00 | Updated Date 11/19/2024 |
Company Size Small-Cap Stock | Market Capitalization 42.98M USD | Price to earnings Ratio - | 1Y Target Price - |
Dividends yield (FY) - | Basic EPS (TTM) - | Volume (30-day avg) 27291 | Beta - |
52 Weeks Range 3.18 - 13.00 | Updated Date 11/19/2024 |
Earnings Date
Report Date - | When - |
Estimate - | Actual - |
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - |
Enterprise Value 176053910 | Price to Sales(TTM) 2358.79 |
Enterprise Value to Revenue 2445.19 | Enterprise Value to EBITDA - |
Shares Outstanding - | Shares Floating - |
Percent Insiders - | Percent Institutions - |
Trailing PE - | Forward PE - | Enterprise Value 176053910 | Price to Sales(TTM) 2358.79 |
Enterprise Value to Revenue 2445.19 | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating - |
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - |
Strong Buy - | Hold - | Sell - |
Strong Sell - |
Rating - | Target Price - | Buy - | Strong Buy - |
Hold - | Sell - | Strong Sell - |
About ABPRO CORP
| Exchange | NYSE | Headquaters | - |
| IPO Launch date | - | CEO | - |
| Sector | Other | Website | www.abpro.com |
| Industry | Other | Full time employees | 42 |
| Headquaters | - | ||
| CEO | - | ||
| Website | www.abpro.com | ||
| Website | www.abpro.com | ||
| Full time employees | 42 |
Abpro Corporation, a biotechnology company, engages in developing antibody therapeutics for patients with immuno-oncology, ophthalmology, and autoimmunity. Its lead product candidates include ABP-100 for the treatment of breast, gastric, and endometrial cancers; and ABP-201 for the treatment of vascular diseases of the eye. Abpro Corporation has a collaboration and license agreements with Essex Bio-Investment Ltd., AbMed Corporation, MedImmune Ltd., and Luye Pharma Group Ltd.; license agreements with Memorial Sloan Kettering Cancer Center and National Cancer Institute; and a partnership agreement with NJCTTQ. The company was formerly known as IE LAB, Inc. and changed its name to Abpro Corporation in September 2007. Abpro Corporation was founded in 2004 and is headquartered in Woburn, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.